The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
EPA guidance on assessment of negative symptoms in schizophrenia
Open accessAbstract
Background: During the last decades, a renewed interest for negative symptoms (NS) was brought about by the increased awareness that they interfere severely with real-life functioning, particularly when they are primary and persistent. Methods: In this guidance paper, we provide a systematic review of the evidence and elaborate several recommendations for the conceptualization and assessment of NS in clinical trials and practice. Results: Expert consensus and systematic reviews have provided guidance for the optimal assessment of primary and persistent negative symptoms; second-generation rating scales, which provide a better assessment of the experiential domains, are available; however, NS are still poorly assessed both in research and clinical settings. This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms. We also encourage clinicians to use second-generation scales, at least to complement first-generation ones. The EPA guidance further recommends the evidence-based exclusion of several items included in first-generation scales from any NS summary or factor score to improve NS measurement in research and clinical settings. Self-rated instruments are suggested to further complement observer-rated scales in NS assessment. Several recommendations are provided for the identification of secondary negative symptoms in clinical settings. Conclusions: The dissemination of this guidance paper may promote the development of national guidelines on negative symptom assessment and ultimately improve the care of people with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121
Reliability and validity of the positive and negative syndrome scale for schizophrenics
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90038-8 · Cited by 1,007
The clinical assessment interview for negative symptoms (CAINS): Final development and validation
Kring, A. M., Gur, R. E., Blanchard, J. J., Horan, W. P., & Reise, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010109 · Cited by 726 · cited 1×
“The development of CAINSwas based on data-driven iterative process leading to several successive versions [29,30,148].”
MethodNegative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias, G., & Remington, G. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn094 · Cited by 594
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585 · cited 1×
“Assessment of negative symptoms in clinical high risk (CHR) individuals 817 As the assessment and treatment of attenuated psychotic symptoms have traditionally been 818 the primary focus in Clinical High Risk (CHR) settings [202,203], less attention has been 819 given to the assessment of negative symptoms.”
BackgroundSelf-citationLlerena, K., Park, S. G., McCarthy, J. M., Couture, S. M., Bennett, M. E., & Blanchard, J. J. (2013) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.12.001 · Cited by 217
The latent structure of negative symptoms in schizophrenia
Strauss, G. P., Nuñez, A., Ahmed, A. O., Barchard, K. A., Granholm, E., Kirkpatrick, B., Gold, J. M., & Allen, D. N. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2475 · Cited by 204 · cited 5×
“In fact, the two-factor model (with experiential and expressive deficit factors) 1075 might be useful to complement total scores in clinical trials, but available confirmatory factor 1076 analyses favor a 5-factor model [37,71-73].”
BackgroundMethodResultInfluential
Metadata
- Authors
- Galderisi, S., Mucci, A., Dollfus, S., Nordentoft, M., Falkai, P., Kaiser, S., Giordano, G. M., Vandevelde, A., Nielsen, M. Ø., Glenthøj, L. B., Sabé, M., Pezzella, P., Bitter, I., & Gaebel, W.
- Venue
- European Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2021
- Volume
- 64
- Issue
- 1
- Pages
- e23-e23
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W3130285778
- Cited by
- 236
- References
- 14
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EPA guidance on assessment of negative symptoms in schizophrenia. https://app.cochat.ai/papers/10.1192/j.eurpsy.2021.11
- The paper
- Galderisi, S., Mucci, A., Dollfus, S., Nordentoft, M., Falkai, P., Kaiser, S., Giordano, G. M., Vandevelde, A., Nielsen, M. Ø., Glenthøj, L. B., Sabé, M., Pezzella, P., Bitter, I., & Gaebel, W. (2021). EPA guidance on assessment of negative symptoms in schizophrenia. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.